

Sandhya Bangaru

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1434386/publications.pdf>

Version: 2024-02-01

19
papers

2,541
citations

516710
16
h-index

794594
19
g-index

28
all docs

28
docs citations

28
times ranked

5807
citing authors

#	ARTICLE	IF	CITATIONS
1	Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. Science, 2020, 369, 643-650.	12.6	1,104
2	Structural analysis of full-length SARS-CoV-2 spike protein from an advanced vaccine candidate. Science, 2020, 370, 1089-1094.	12.6	290
3	Cross-Neutralization of a SARS-CoV-2 Antibody to a Functionally Conserved Site Is Mediated by Avidity. Immunity, 2020, 53, 1272-1280.e5.	14.3	185
4	A Site of Vulnerability on the Influenza Virus Hemagglutinin Head Domain Trimer Interface. Cell, 2019, 177, 1136-1152.e18.	28.9	177
5	An Alternative Binding Mode of IGHV3-53 Antibodies to the SARS-CoV-2 Receptor Binding Domain. Cell Reports, 2020, 33, 108274.	6.4	152
6	Bispecific antibodies targeting distinct regions of the spike protein potentially neutralize SARS-CoV-2 variants of concern. Science Translational Medicine, 2021, 13, eabj5413.	12.4	79
7	A multifunctional human monoclonal neutralizing antibody that targets a unique conserved epitope on influenza HA. Nature Communications, 2018, 9, 2669.	12.8	67
8	H7N9 influenza virus neutralizing antibodies that possess few somatic mutations. Journal of Clinical Investigation, 2016, 126, 1482-1494.	8.2	62
9	A natural mutation between SARS-CoV-2 and SARS-CoV determines neutralization by a cross-reactive antibody. PLoS Pathogens, 2020, 16, e1009089.	4.7	55
10	Structural Basis of Protection against H7N9 Influenza Virus by Human Anti-N9 Neuraminidase Antibodies. Cell Host and Microbe, 2019, 26, 729-738.e4.	11.0	51
11	Influenza H7N9 Virus Neuraminidase-Specific Human Monoclonal Antibodies Inhibit Viral Egress and Protect from Lethal Influenza Infection in Mice. Cell Host and Microbe, 2019, 26, 715-728.e8.	11.0	49
12	A combination of cross-neutralizing antibodies synergizes to prevent SARS-CoV-2 and SARS-CoV pseudovirus infection. Cell Host and Microbe, 2021, 29, 806-818.e6.	11.0	49
13	Potent anti-influenza H7 human monoclonal antibody induces separation of hemagglutinin receptor-binding head domains. PLoS Biology, 2019, 17, e3000139.	5.6	37
14	Structure and immune recognition of the porcine epidemic diarrhea virus spike protein. Structure, 2021, 29, 385-392.e5.	3.3	37
15	Structural mapping of antibody landscapes to human betacoronavirus spike proteins. Science Advances, 2022, 8, eabn2911.	10.3	28
16	Canonical features of human antibodies recognizing the influenza hemagglutinin trimer interface. Journal of Clinical Investigation, 2021, 131, .	8.2	20
17	Recognition of influenza H3N2 variant virus by human neutralizing antibodies. JCI Insight, 2016, 1, .	5.0	20
18	Murine Monoclonal Antibodies against the Receptor Binding Domain of SARS-CoV-2 Neutralize Authentic Wild-Type SARS-CoV-2 as Well as B.1.1.7 and B.1.351 Viruses and Protect <i>In Vivo</i> in a Mouse Model in a Neutralization-Dependent Manner. MBio, 2021, 12, e0100221.	4.1	7

#	ARTICLE	IF	CITATIONS
19	Human antibody recognition of H7N9 influenza virus HA following natural infection. JCI Insight, 2021, 6, .	5.0	1